Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

948 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.
Gangat N, Johnson I, McCullough K, Farrukh F, Al-Kali A, Alkhateeb H, Begna K, Mangaonkar A, Litzow M, Hogan W, Shah M, Patnaik M, Pardanani A, Tefferi A. Gangat N, et al. Among authors: johnson i. Haematologica. 2022 Oct 1;107(10):2501-2505. doi: 10.3324/haematol.2022.281214. Haematologica. 2022. PMID: 35770533 Free PMC article. No abstract available.
Osteolytic lesions in myelofibrosis.
Johnson I, Alkhateeb H. Johnson I, et al. Clin Case Rep. 2021 Jul 19;9(7):e04276. doi: 10.1002/ccr3.4276. eCollection 2021 Jul. Clin Case Rep. 2021. PMID: 34295475 Free PMC article.
Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.
Gangat N, McCullough K, Johnson I, Al-Kali A, Begna KH, Patnaik MM, Litzow MR, Hogan W, Shah M, Alkhateeb H, Mangaonkar A, Foran JM, Badar T, Palmer JM, Sproat L, Arana Yi CY, Pardanani A, Tefferi A. Gangat N, et al. Among authors: johnson i. Am J Hematol. 2022 Jun 1;97(6):E214-E216. doi: 10.1002/ajh.26539. Epub 2022 Mar 24. Am J Hematol. 2022. PMID: 35303376 Free article. No abstract available.
Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma.
Acosta-Medina AA, Johnson IM, Bansal R, Hathcock M, Kenderian SJ, Durani U, Khurana A, Wang Y, Paludo J, Villasboas JC, Bennani NN, Johnston PB, Ansell SM, Lin Y, Alkhateeb HB. Acosta-Medina AA, et al. Blood Cancer J. 2023 Jan 5;13(1):7. doi: 10.1038/s41408-022-00777-4. Blood Cancer J. 2023. PMID: 36599834 Free PMC article. No abstract available.
Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
Acosta-Medina AA, Baranwal A, Johnson IM, Kharfan-Dabaja MA, Murthy H, Palmer JM, Sproat L, Mangaonkar A, Shah MV, Hogan WJ, Litzow MR, Tefferi A, Alkhateeb HB. Acosta-Medina AA, et al. Transplant Cell Ther. 2023 Jun;29(6):360.e1-360.e8. doi: 10.1016/j.jtct.2023.02.002. Epub 2023 Feb 9. Transplant Cell Ther. 2023. PMID: 36773650 Free article.
Outcome of patients with acute myeloid leukemia following failure of frontline venetoclax plus hypomethylating agent therapy.
Gangat N, Ilyas R, Johnson IM, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Tefferi A. Gangat N, et al. Haematologica. 2023 Nov 1;108(11):3170-3174. doi: 10.3324/haematol.2022.282677. Haematologica. 2023. PMID: 36861409 Free PMC article. No abstract available.
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Gangat N, et al. Am J Hematol. 2024 Feb;99(2):193-202. doi: 10.1002/ajh.27138. Epub 2023 Dec 10. Am J Hematol. 2024. PMID: 38071734
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma.
Cook J, Johnson I, Higgins A, Sidana S, Warsame R, Gonsalves W, Gertz MA, Buadi F, Lacy M, Kapoor P, Dispenzieri A, Kourelis T, Dingli D, Fonder A, Hayman S, Hobbs M, Hwa YL, Kyle R, Leung N, Go R, Rajkumar VS, Kumar S. Cook J, et al. Among authors: johnson i. Am J Hematol. 2021 Mar 1;96(3):330-337. doi: 10.1002/ajh.26074. Epub 2021 Jan 13. Am J Hematol. 2021. PMID: 33326116 Free article.
948 results